Sequence-dependent synergistic cytotoxicity of ectein]ascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo

Cancer Research

Volumn 62, Issue 23, 2002, Pages 6909-6915

  Takahashi, Naoto ^a,b   Li, WeiWei ^a   Banerjee, Debabrata ^a   Guan, Yongbiao ^a   Wada Takahashi, Yasuko ^a   Brennan, Murray F ^a   Chou, Ting Chao ^a   Scotto, Kathleen W ^a   Bertino, Joseph R ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL; TRABECTEDIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CISPLATIN; DIOXOLES; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; MICE; MICE, NUDE; MITOSIS; P-GLYCOPROTEIN; PACLITAXEL; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036894384     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Li, L. H., and Martin, D. G. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem., 55: 4512-4515, 1990.
2. Valoti, G., Nicoletti, M. I., Pellerbino, A., Jimeno, J., Hendricks, H., D'Incalci, M., Faircloth, G., and Giavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor active on human ovarian carcinoma xenografts. Clin. Cancer Res., 4: 1977-1983, 1998.
3. Hendricks, H. R., Fiebig, H. H., Giavazzi, R., Langdon, S. P., Jimeno, J. M., and Faircloth, G. T. High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small cell lung and ovarian cancer. Ann. Oncol., 10: 1233-1240, 1999.
4. Izbicka, E., Lawrence, R., Raymond, E., Eckhardt, G., Faircloth, G., Jimeno, J., Clark, G., and Von Hoff, D. D. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET743, NSC-648766) against human tumors explanted from patients. Ann. Oncol., 9: 981-987, 1998.
5. Demetri, G. D., Seiden, M., Garcia-Carbonero, R., Supko, J., Harmon, D., Goss, G., Robinson, L., Merriam, P., Waxman, A., Quigley, M. T., Jimeno, J., and Ryan, D. P. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: Summary of 3 U.S.-based Phase II trials. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 553, 2000.
6. Pommier Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinatu. Biochemistry, 35: 13303-13309, 1996.
7. Takabayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y. Poisoning of human DNA topoisomerase I by Ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA. 96: 7196-7201, 1999.
8. Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W. Ecteinascidin 743, a transcription-target chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA, 97: 6775-6779, 2000.
9. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., and Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidine-743. Proc. Natl. Acad. Sci. USA, 97: 6780-6784, 2000.
10. American Cancer Society. Cancer Facts and Figures-1997. New York: American Cancer Society, Inc., 1997.
11. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul., 22: 27-55, 1984.
12. Chou, T. C., Riedeout, D., Chou, J., and Bertino, J. R. Chemotherapeutic synergism, potential and antagonism. In: R. Dulbecco (ed.), Encyclopedia of Human Biology, Vol. 2, pp. 371-379. San Diego, CA: Academic Press, 1991.
13. Chou, T. C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: T. C. Chou and D. C. Rideout (eds.), Synergism and Antagonism in Chemotherapy, pp. 61-102. San Diego, CA: Academic Press, 1991.
14. Chou, T. C., Motzer, R. J., Tong, Y., and Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against teratocarcinoma cell growth: A rational approach to clinical protocol design. J. Natl. Cancer. Inst. (Bethesda). 86: 1517-1524, 1994.
15. Chou, T-C., and Hayball, M. CalcuSyn for Windows. Multiple-Drug Dose-Effect Analyzer and Manual. Biosoft, Cambridge Place, Cambridge, United Kingdom, 1996.
16. Chou, J., and Chou, T. C. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: T. C. Chou and D. C. Rideout (eds.), Synergism and Antagonism in Chemotherapy, pp. 223-244. San Diego, CA: Academic Press, 1991.
17. Skehan, P., Stoeng, R., Monks, A., McMahon, J., Vistica, D., Warrent, J. T., Bokesch, H., Kenny, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer. Inst. (Bethesda), 82: 1107-1112, 1990.
18. Motwani, M., Delohery, T. M., and Schwartz, G. M. Sequential-dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876-1883, 1999.
19. D'Incalci, M. Mode of action of ecteinercidin-743 (ET-743). Molecular targets and cancer therapeutics. Proceeding of the AACR-NC1-EORTC International Conference. 11: 144-145, 1999.
20. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., and D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compounds, with a unique mechanism of action. Eur. J. Cancer, 37: 97-105. 2001.
21. Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., and Pommier, Y. Ecteinascidin 743 induces protein-liked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin. Cancer Res., 7: 185-191, 2001.
22. Panvichian, R., Orth, K., Day, M. D., Day, K. D., Pilat, M. J., and Pienta, K. J. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: A potential early step in drug resistance. Cancer Res., 58: 4667-4672, 1998.
23. Synold, T. W., Dussault, I., and Forman, B. M. the orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 7: 584-590, 2001.